Li Yu, Zhang Keying, Yang Fa, Jiao Dian, Li Mingyang, Zhao Xiaolong, Xu Chao, Liu Shaojie, Li Hongji, Shi Shengjia, Yang Bo, Yang Lijun, Han Donghui, Wen Weihong, Qin Weijun
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Department of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Front Oncol. 2021 Nov 17;11:771036. doi: 10.3389/fonc.2021.771036. eCollection 2021.
Urothelial carcinoma of the bladder (UCB) is a common cancer of the urinary system. Despite substantial improvements in available treatment options, the survival outcome of patients with advanced UCB is unsatisfactory. Therefore, it is necessary to identify new prognostic biomarkers for monitoring and therapy guidance of UCB. In recent years, prostate-specific membrane antigen (PSMA) and CD248 have been identified promising candidate bio7markers.
In this study, we first examined PSMA and CD248 expression in tissues from 124 patients with UCB using immunohistochemical and immunofluorescent staining. We then analyzed the association between the expression of the two biomarkers and other clinicopathological features and prognosis. Finally, we performed bioinformatic analysis of and using the TCGA-BLCA dataset to explore the underlying mechanism of PSMA and CD248 in the progression of UCB.
Among the 124 cases, PSMA and CD248 were confirmed to be expressed in tumor-associated vessels. Vascular PSMA and CD248 expression levels were associated significantly with several deteriorated clinicopathological features. Furthermore, using univariate and multivariate Cox analyses, high vascular PSMA and CD248 expression levels were observed to be associated significantly with poor prognosis in patients with UCB. As risk factors, both PSMA and CD248 expression showed good performance to predict prognosis. Furthermore, combining these vascular molecules with other clinical risk factors generated a risk score that could promote predictive performance. Bioinformatic analysis showed that both PSMA and CD248 might contribute to angiogenesis and promote further progression of UCB.
Both PSMA and CD248 are specifically expressed in the tumor-associated vasculature of UCB. These two molecules might be used as novel prognostic biomarkers and vascular therapeutic targets for UCB.
膀胱尿路上皮癌（UCB）是泌尿系统的一种常见癌症。尽管现有治疗方案有了显著改善，但晚期UCB患者的生存结局仍不尽人意。因此，有必要识别新的预后生物标志物，用于UCB的监测和治疗指导。近年来，前列腺特异性膜抗原（PSMA）和CD248已被确定为有前景的候选生物标志物。
在本研究中，我们首先使用免疫组织化学和免疫荧光染色检测了124例UCB患者组织中PSMA和CD248的表达。然后，我们分析了这两种生物标志物的表达与其他临床病理特征及预后之间的关联。最后，我们使用TCGA - BLCA数据集对PSMA和CD248进行生物信息学分析，以探索它们在UCB进展中的潜在机制。
在124例病例中，证实PSMA和CD248在肿瘤相关血管中表达。血管PSMA和CD248表达水平与一些恶化的临床病理特征显著相关。此外，通过单因素和多因素Cox分析，观察到高血管PSMA和CD248表达水平与UCB患者的不良预后显著相关。作为风险因素，PSMA和CD248表达在预测预后方面均表现良好。此外，将这些血管分子与其他临床风险因素相结合产生的风险评分可提高预测性能。生物信息学分析表明，PSMA和CD248都可能促进血管生成并推动UCB的进一步进展。
PSMA和CD248均在UCB的肿瘤相关脉管系统中特异性表达。这两种分子可能用作UCB的新型预后生物标志物和血管治疗靶点。
